Navigation Links
Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine

ROCKVILLE, Md., Feb. 23 /PRNewswire/ -- Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support collaborative research by investigators at Sanaria and Columbia University. This new funding extends previous NIAID supported efforts at Sanaria and Columbia to develop genetically modified strains of the human malaria parasite Plasmodium falciparum that are unable to cause disease, yet stimulate protective immunity when administered as a live, whole parasite malaria vaccine. "There is considerable excitement about whole parasite malaria vaccines, and research towards developing genetically modified strains for such vaccines is at the cutting edge of this field," states Dr. Christian Loucq, Director of the PATH Malaria Vaccine Initiative.

Sporozoite stage parasites that have been weakened (attenuated) by exposure to radiation confer high-level protection against malaria when introduced by the bite of infected mosquitoes. The attenuated parasites invade host tissues, but cannot complete differentiation and therefore do not replicate or cause disease. Sanaria has developed technologies and built a facility to manufacture a radiation attenuated sporozoite vaccine that can be administered by injection and has met FDA regulatory standards for initial clinical evaluation.  This vaccine candidate, the SanariaTM PfSPZ Vaccine, is now being assessed in clinical trials. According to Dr. Stephen L. Hoffman, Sanaria's founder and chief scientist, "Sanaria is uniquely positioned at this time to expand the pipeline of candidate sporozoite vaccines to include vaccines based on precisely gene-altered parasites that are highly potent in inducing protective immunity against malaria and are unable to cause disease."

"Sanaria's proven ability to manufacture whole sporozoite vaccines in compliance with FDA standards means that promising new strains of the malaria parasite that are being developed in our research laboratory can be efficiently translated into prototype candidate vaccines suitable for testing in the clinic," says Dr. David Fidock of Columbia University. Dr. Robert Sauerwein of the Radboud University Nijmegen Medical Centre, whose laboratory in collaboration with Sanaria has generated several genetically attenuated strains of Plasmodium falciparum concurs, stating, "This is a very exciting opportunity to make significant strides that will facilitate translation from the laboratory to clinical studies of a vialed, genetically attenuated, sporozoite vaccine inoculated by needle and syringe."  

About Sanaria Inc.

Sanaria Inc. was founded in 2003.  The company's primary mission is to develop and commercialize attenuated whole-parasite malaria vaccines that confer high-level, long-lasting protection against Plasmodium falciparum, the parasite responsible for most of the malaria-associated severe illness and death worldwide. Sanaria's radiation attenuated sporozoite vaccine, SanariaTM PfSPZ Vaccine, entered clinical trials in 2009. Sanaria's corporate headquarters, administrative, research, development, and manufacturing operations are located in Rockville, Maryland. The company's Web site is

Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risk and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements.

For further information contact:
Media- Adam Richman 301.770.3222, Investors- Robert Thompson 240.403.2750

SOURCE Sanaria Inc.

Back to top



SOURCE Sanaria Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
2. Agendia Receives New York State Laboratory Permit and Laboratory Accreditation by College of American Pathologists
3. UH Superconductivity Center Receives Texas Emerging Technology Fund Award
4. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
5. UC Riverside graphene specialist Jeanie Lau receives national honor at White House
6. Eribis Pharmaceuticals Receives Investment for Clinical Development of Novel Cardiovascular Therapy
7. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
8. BioCrysts Partner Shionogi Receives Marketing & Manufacturing Approval For Peramivir in Japan
9. Fibrocell Science, Inc. Receives FDA Complete Response Letter Regarding azficel-T for Wrinkles
10. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
11. Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: ... been advised by its major shareholders, Clean Technology Fund ... United States based venture capital funds ... of Biorem (on a fully diluted, as converted basis), ... disposition of their entire equity holdings in Biorem to ...
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer ... what they believe could be a new and helpful biomarker for malignant pleural ... Click here to read it now. , Biomarkers are components in the ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):